PURPOSE: The aim of this pharmacokinetic-pharmacodynamic (PK-PD) analysis was to evaluate the pharmacologic characteristics of erlotinib and its main metabolite (OSI-420) in pediatric patients compared with those in adult patients. EXPERIMENTAL DESIGN: Plasma concentrations of erlotinib and OSI-420 of 46 children with malignant brain tumors included in a phase I study and 42 adults with head and neck carcinoma were analyzed by a population-pharmacokinetic method (NONMEM). The effect of several covariates and single nucleotide polymorphisms (SNP) in ABCB1, ABCG2, and CYP3A5 on pharmacokinetic parameters was evaluated. PK/PD relationships between plasma drug exposure Area Under the Curve (AUC) at day 1 and skin toxicity were studied in children and compared with the relationship observed in adults. RESULTS: A significant difference in erlotinib clearance (P = 0.0001), when expressed in L·h(-1)·kg(-1), was observed between children and adults with mean values of 0.146 and 0.095, respectively (mean difference = 0.051 L·h(-1)·kg(-1), SD = 0.0594). However, a common covariate model was obtained describing erlotinib clearance according to body weight, alanine aminotransferase, ABCB1, and CYP3A5 polymorphisms (2677G > T/A and 6986G > A) for both children and adult patients. The PK-PD relationship was very consistent between the children and adult groups with risk of skin toxicity rising with increasing erlotinib AUC. CONCLUSIONS: The nonlinear population approach applied to pharmacokinetic data combined with a pharmacokinetic-pharmacodynamic analysis revealed that the higher recommended dose in children (125 mg/m(2)/day) compared with adults (90 mg/m(2)/day) is mainly due to pharmacokinetic rather than pharmacodynamic particularities.
PURPOSE: The aim of this pharmacokinetic-pharmacodynamic (PK-PD) analysis was to evaluate the pharmacologic characteristics of erlotinib and its main metabolite (OSI-420) in pediatric patients compared with those in adult patients. EXPERIMENTAL DESIGN: Plasma concentrations of erlotinib and OSI-420 of 46 children with malignant brain tumors included in a phase I study and 42 adults with head and neck carcinoma were analyzed by a population-pharmacokinetic method (NONMEM). The effect of several covariates and single nucleotide polymorphisms (SNP) in ABCB1, ABCG2, and CYP3A5 on pharmacokinetic parameters was evaluated. PK/PD relationships between plasma drug exposure Area Under the Curve (AUC) at day 1 and skin toxicity were studied in children and compared with the relationship observed in adults. RESULTS: A significant difference in erlotinib clearance (P = 0.0001), when expressed in L·h(-1)·kg(-1), was observed between children and adults with mean values of 0.146 and 0.095, respectively (mean difference = 0.051 L·h(-1)·kg(-1), SD = 0.0594). However, a common covariate model was obtained describing erlotinib clearance according to body weight, alanine aminotransferase, ABCB1, and CYP3A5 polymorphisms (2677G > T/A and 6986G > A) for both children and adult patients. The PK-PD relationship was very consistent between the children and adult groups with risk of skin toxicity rising with increasing erlotinib AUC. CONCLUSIONS: The nonlinear population approach applied to pharmacokinetic data combined with a pharmacokinetic-pharmacodynamic analysis revealed that the higher recommended dose in children (125 mg/m(2)/day) compared with adults (90 mg/m(2)/day) is mainly due to pharmacokinetic rather than pharmacodynamic particularities.
Authors: Johan G C van Hasselt; Natasha K A van Eijkelenburg; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Br J Clin Pharmacol Date: 2013-07 Impact factor: 4.335
Authors: M A Phelps; T E Stinchcombe; J S Blachly; W Zhao; L J Schaaf; S L Starrett; L Wei; M Poi; D Wang; A Papp; J Aimiuwu; Y Gao; J Li; G A Otterson; W J Hicks; M A Socinski; M A Villalona-Calero Journal: Clin Pharmacol Ther Date: 2014-04-29 Impact factor: 6.875
Authors: Samuel J Reddick; Olivia Campagne; Jie Huang; Arzu Onar-Thomas; Alberto Broniscer; Amar Gajjar; Clinton F Stewart Journal: Cancer Chemother Pharmacol Date: 2019-08-07 Impact factor: 3.333
Authors: Nabil F Saba; Selwyn J Hurwitz; Scott A Kono; Chung S Yang; Yang Zhao; Zhengjia Chen; Gabe Sica; Susan Müller; Rachel Moreno-Williams; Melinda Lewis; William Grist; Amy Y Chen; Charles E Moore; Taofeek K Owonikoko; Suresh Ramalingam; Jonathan J Beitler; Sreenivas Nannapaneni; Hyung Ju C Shin; Jennifer R Grandis; Fadlo R Khuri; Zhuo Georgia Chen; Dong M Shin Journal: Cancer Prev Res (Phila) Date: 2013-10-03
Authors: N Gaspar; L V Marshall; D Binner; R Herold; R Rousseau; P Blanc; R Capdeville; J Carleer; C Copland; Y Kerloeguen; K Norga; L Pacaud; M-A Sevaux; C Spadoni; J Sterba; F Ligas; T Taube; M Uttenreuther-Fischer; S Chioato; M A O'Connell; B Geoerger; J-Y Blay; J C Soria; S Kaye; B Wulff; L Brugières; G Vassal; A D J Pearson Journal: Ann Oncol Date: 2018-03-01 Impact factor: 32.976